Filing Overview
Source filing: Selecta Biosciences, Inc. Form 10-K for the fiscal year ended December 31, 2021, filed March 10, 2022. The request metadata identifies Cartesian Therapeutics, Inc.; the supplied filing is for Selecta Biosciences, Inc. and does not mention Cartesian Therapeutics. The filing covers the full 2021 fiscal year rather than only fourth-quarter results.
Business Context and Reporting Period
Selecta was a clinical-stage biopharmaceutical company developing the ImmTOR platform, which uses biodegradable rapamycin nanoparticles intended to induce antigen-specific immune tolerance and reduce anti-drug antibodies. Principal programs included SEL-212 for chronic refractory gout, gene-therapy applications, IgA nephropathy, and autoimmune diseases using ImmTOR or ImmTOR-IL.
- SEL-212 was in Phase 3 DISSOLVE I and DISSOLVE II trials, with DISSOLVE I enrollment completed in December 2021.
- Top-line DISSOLVE data were expected in the fourth quarter of 2022.
- SEL-302 for methylmalonic acidemia had been placed on FDA clinical hold in November 2021 due to AAV chemistry, manufacturing and controls questions; the hold was removed on March 9, 2022.
- The company had 58 employees as of December 31, 2021, including 44 primarily engaged in research and development.
Financial Performance and Position
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Collaboration and license revenue | $85.1 million | $16.6 million | +$68.5 million, or 413% |
| Research and development expense | $68.7 million | $54.5 million | +$14.2 million, or 26% |
| General and administrative expense | $20.9 million | $18.9 million | +$2.0 million, or 11% |
| Operating loss | $4.6 million | $56.8 million | Improved by $52.2 million |
| Net loss | $25.7 million | $68.9 million | Improved by $43.2 million |
| Basic and diluted loss per share | $0.22 | $0.68 | Improved |
| Net cash used in operating activities | $60.4 million | $34.9 million provided | Negative swing of $95.3 million |
Revenue was primarily collaboration and license revenue rather than product sales. Sobi-related revenue was $83.5 million in 2021, including reimbursement of Phase 3 DISSOLVE costs and revenue associated with clinical supply. Takeda contributed $1.0 million, Sarepta contributed $0.4 million, and the Skolkovo grant contributed $0.1 million.
The 2021 net loss included $16.0 million of income tax expense, primarily resulting from the company’s election to opt out of installment-sale tax treatment for the Sobi transaction. The company also recorded a $2.3 million loss from remeasurement of warrant liabilities and $2.8 million of interest expense.
| Balance sheet metric | December 31, 2021 |
|---|---|
| Cash and cash equivalents | $114.1 million |
| Marketable securities | $14.0 million |
| Restricted cash | $1.4 million |
| Total liquidity including cash, equivalents, restricted cash and marketable securities | $129.4 million |
| Total debt principal | $25.0 million |
| Warrant liabilities | $25.4 million |
| Accumulated deficit | $430.3 million |
| Stockholders’ equity | $22.5 million |
Management stated that existing cash, cash equivalents, restricted cash and marketable securities were expected to fund current planned operations into the third quarter of 2023, subject to operational performance, collaboration milestones and financing conditions. The financial statement notes state that liquidity would fund operations for at least the next twelve months from issuance of the financial statements.
Material Changes Versus the Prior Comparable Period
- Collaboration and license revenue increased substantially because the Phase 3 Sobi program progressed and related supply and reimbursable costs were recognized.
- Research and development spending increased 26%, driven by preclinical programs, additional personnel, AskBio collaboration costs, and $4.0 million and $0.5 million upfront payments to Genovis and Ginkgo, respectively.
- Operating cash flow turned negative, primarily because deferred revenue declined by $45.5 million and operating assets and liabilities used approximately $48.2 million of cash.
- The company raised $51.9 million of net proceeds through at-the-market equity offerings and issued 13.8 million shares during 2021. Shares outstanding increased to 123.6 million from 108.1 million.
- Warrant liabilities declined to $25.4 million from $28.7 million after warrant exercises, although fair-value remeasurement produced a $2.3 million loss.
- The company entered into agreements with Takeda, Ginkgo, Genovis and Cyrus, including a $2.0 million investment in Cyrus preferred stock and a potential Cyrus milestone obligation of approximately $1.5 billion across multiple programs.
- AskBio opted out of developing the MMA indication, leaving Selecta responsible for advancing SEL-302.
Guidance, Outlook, Risks and Unusual Items
- Outlook: Management expected continued operating losses and substantial additional funding needs. No product revenue was expected for the foreseeable future.
- Clinical milestones: SEL-212 DISSOLVE top-line data were expected in the fourth quarter of 2022. DISSOLVE II enrollment faced potential disruption from the Russia-Ukraine conflict; screening and randomization at sites in Russia and Ukraine were temporarily closed and 11 U.S. sites were added.
- Liquidity risk: The cash runway estimate depends on assumptions that may prove incorrect. Additional equity, debt, licensing or collaboration financing may be required and could dilute stockholders or impose restrictive terms.
- Debt: The $25.0 million term loan matures in August 2025, bears interest at a minimum stated rate of 7.90%, requires interest-only payments through April 2022, and is secured by substantially all assets other than intellectual property. Principal payments begin thereafter.
- Revenue recognition judgment: The auditor identified Sobi revenue recognition as a critical audit matter. The company recognized $83.5 million of Sobi revenue based partly on estimates of total clinical supply requirements and progress under the DISSOLVE program.
- Manufacturing and supply: Pegadricase is primarily supplied by 3SBio in China. The company relies on third-party manufacturers and has limited redundant supply arrangements.
- COVID-19 and geopolitical risks: The filing cites possible enrollment, supply-chain, site-operation and regulatory delays from COVID-19, the Russia-Ukraine conflict, sanctions and broader macroeconomic instability.
- Legal contingency: A stockholder derivative action related to the December 2019 private placement was stayed while settlement discussions proceeded. The company accrued an estimated $0.9 million liability and expected court approval of a settlement.
- Subsequent events: In January 2022, Selecta entered into a second Ginkgo agreement relating to AAV capsids. After year-end, it sold 576,418 shares through its ATM program for $1.7 million of net proceeds.
Investor Verification Checklist
- Verify the company identity: the supplied filing is Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc.
- Review the audited financial statements and Note 12 for the sustainability, timing and estimates underlying the $85.1 million of 2021 collaboration revenue, particularly the $83.5 million from Sobi.
- Confirm the actual DISSOLVE I and DISSOLVE II results, regulatory status and commercial prospects relative to the expected fourth-quarter 2022 timeline.
- Assess cash burn, debt amortization beginning in April 2022, and the likelihood and terms of future financing.
- Evaluate dilution from the 2021 ATM issuance, outstanding options, restricted stock units and 10.7 million outstanding warrants.
- Monitor supply, manufacturing and geopolitical exposure involving 3SBio, Russia, Ukraine and third-party contract manufacturers.
- Review the status and final terms of the stockholder litigation settlement and any related legal or governance implications.